Acrylic acid microsphere carrying paclitaxel drug
By designing honeycomb acrylic microspheres loaded with paclitaxel, the problems of poor water solubility and high toxicity of paclitaxel were solved, achieving high drug loading and sustained release effect of the microspheres, thus improving the efficacy of endovascular interventional therapy.
Patent Information
- Application Number
- CN202322792425.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-29
- Filing Date
- 2023-10-18
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the existing technology, paclitaxel drugs have poor water solubility and high toxicity, and there is a lack of microspheres that can be carried and slowly released for interventional treatment to prevent and treat vascular restenosis.
A honeycomb acrylic microsphere was designed to load paclitaxel through surface and internal adsorption forces, forming regular and uniformly dispersed microspheres with a particle size of 10–500 μm, a drug loading of 380 ± 21 μg paclitaxel/mg microsphere, and an encapsulation efficiency of 10% ± 1.2%, for use in endovascular interventional therapy.
The microspheres exhibit good biocompatibility and stability, strong drug loading capacity, significant sustained-release effect, and low toxicity. They can effectively inhibit vascular endothelial cells and smooth muscle cells, thereby improving clinical efficacy.
Smart Images

Figure CN222033121U_ABST
Abstract
Description
Technical Field
[0001] The utility model relates to the technical field of embolic microspheres, in particular to acrylic microspheres carrying paclitaxel drugs. Background Art
[0002] Paclitaxel can inhibit both vascular smooth muscle cells and endothelial cells. Paclitaxel-coated devices have been widely used in the prevention and treatment of vascular restenosis after interventional therapy. However, paclitaxel has poor water solubility and high drug toxicity, and there are no microspheres that can carry paclitaxel and release it slowly. Utility Model Content
[0003] In order to solve the above technical problems, the utility model provides an acrylic microsphere carrying paclitaxel drug.
[0004] The purpose of this utility model is mainly achieved through the following technical solutions:
[0005] The utility model provides an acrylic microsphere carrying paclitaxel drug, comprising:
[0006] The microspheres are honeycomb-shaped as a whole, and the microspheres are acrylic microspheres;
[0007] The load is arranged on the surface and inside of the microspheres, and the load is paclitaxel.
[0008] Furthermore, the microspheres have a particle size of 10 to 500 μm.
[0009] Furthermore, any cut surface of the microsphere is a honeycomb structure.
[0010] Furthermore, the amount of the loading substance is set to 380±21ug paclitaxel / mg microsphere.
[0011] Compared with the prior art, the present invention can achieve at least one of the following beneficial effects:
[0012] (1) The microspheres of the utility model are regular and evenly dispersed, have good biocompatibility and stability, have rich honeycomb structures on the surface and inside, have strong drug loading capacity and good sustained release effect;
[0013] (2) The acrylic microspheres carrying paclitaxel of the utility model have a drug loading (i.e., the amount of the load): 380±21ug paclitaxel / mg microsphere; encapsulation rate: 10%±1.2%; cytotoxicity and blood compatibility experiments have verified that they meet the standards; in vivo release experiments have confirmed that paclitaxel can be detected in the blood within 4 days after embolization, and in vitro release experiments have confirmed that the cumulative drug release in 7 days reaches 46%;
[0014] (3) The acrylic microspheres carrying paclitaxel drugs of the utility model are drug-loaded microspheres that can be used for intravascular interventional treatment. They not only have a good embolization effect, but also have a small toxic and side effect of paclitaxel sustained-release drugs and can effectively inhibit vascular endothelial cells and smooth muscle cells, thereby improving clinical efficacy.
[0015] In the present invention, the above-mentioned technical solutions can also be combined with each other to achieve more preferred combination solutions. Other features and advantages of the present invention will be described in the following content, and some advantages can be obvious from the description or understood by implementing the present invention. The purpose and other advantages of the present invention can be achieved and obtained through the contents specifically pointed out in the text and the drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The accompanying drawings are only used for the purpose of illustrating specific embodiments and are not to be considered as limiting the present invention. In the entire drawings, the same reference symbols represent the same components.
[0017] Figure 1 This is a schematic diagram of the structure of acrylic microspheres carrying paclitaxel drugs in a specific embodiment;
[0018] Figure 2 This is a schematic diagram of the cross-sectional structure of acrylic microspheres carrying paclitaxel drugs in a specific embodiment;
[0019] Figure 3 is a loading curve diagram of paclitaxel loaded onto blank microspheres in a specific embodiment;
[0020] Figure 4 The figure is a release curve of paclitaxel from acrylic microspheres carrying paclitaxel in a phosphate buffer solution in a specific embodiment.
[0021] Reference numerals:
[0022] 1-microsphere; 2-load. DETAILED DESCRIPTION
[0023] The preferred embodiments of the present invention are described in detail below in conjunction with the accompanying drawings, wherein the accompanying drawings constitute a part of the present invention and are used together with the embodiments of the present invention to illustrate the principles of the present invention, but are not used to limit the scope of the present invention.
[0024] In the description of the embodiments of the present utility model, it should be noted that, unless otherwise clearly specified and limited, the term "connected" should be understood in a broad sense, for example, it can be a fixed connection, or a detachable connection, or an integral connection can be a mechanical connection, or an electrical connection can be a direct connection, or it can be indirectly connected through an intermediate medium. For ordinary technicians in this field, the specific meanings of the above terms in the present utility model can be understood according to specific circumstances.
[0025] The terms "top", "bottom", "above", "lower", and "on" used throughout the description are relative to the relative positions of components of a device, such as the relative positions of the top and bottom substrates within a device. It is understood that devices are multifunctional regardless of their orientation in space.
[0026] The common working surface of the utility model can be a plane or a curved surface, can be inclined, or can be horizontal. For the convenience of description, the embodiment of the utility model is placed on a horizontal plane and used on the horizontal plane, and "high and low" and "up and down" are defined in this way.
[0027] A specific embodiment of the utility model discloses an acrylic microsphere carrying paclitaxel drug, such as Figure 1 and Figure 2 As shown, including:
[0028] Microsphere 1, which is honeycomb-shaped as a whole, and is acrylic microsphere;
[0029] The load 2 is disposed on the surface and inside of the microsphere 1, and the load 2 is paclitaxel. Specifically, the load 2 is disposed on the surface and inside of the microsphere 1 by the surface adsorption force of the honeycomb microsphere 1, that is, the load 2 is distributed on the surface of the microsphere 1 and the internal honeycomb surface by the surface adsorption force.
[0030] The acrylic microspheres carrying paclitaxel drugs of the utility model are drug-loaded microspheres that can be used for intravascular interventional treatment. They not only have good embolization effects, but also have small toxic and side effects of paclitaxel sustained-release drugs and can well inhibit vascular endothelial cells and smooth muscle cells, thereby improving clinical efficacy.
[0031] The microsphere 1 has a regular spherical shape, good biocompatibility and stability, a rich honeycomb structure on the surface and inside, a strong drug loading capacity and a good sustained release effect. Furthermore, the microsphere 1 has a particle size of 10 to 500 μm.
[0032] The microsphere 1 is formed by cross-linking polyvinyl alcohol and acrylic acid. The microsphere 1 has a rich honeycomb structure on the surface and a rich honeycomb structure inside any cut surface.
[0033] It should be noted that the present invention protects the structure of acrylic microspheres carrying paclitaxel drugs, and how the paclitaxel load is specifically loaded is not the focus of the present application. As long as the method of setting the paclitaxel load on the surface and inside of the microsphere is applicable to the present invention. For example, the traditional physical adsorption deposition method can be used to set paclitaxel on the surface and inside of the microsphere. Specifically, the microsphere is immersed in a paclitaxel-ethanol solution, stirred for drug loading, and the acrylic microsphere carrying the paclitaxel drug is obtained after natural drying. The method uses the principle that paclitaxel is easily soluble in ethanol and ethanol is easily volatile. By immersing the microsphere in a paclitaxel buffer solution, the paclitaxel load can be loaded on the microsphere after natural drying. The electron microscope scanning results show that the paclitaxel load can indeed be loaded on the acrylic microsphere. Preferably, the concentration of the paclitaxel-ethanol solution is 50 mg / mL. The ethanol in the paclitaxel-ethanol solution is anhydrous ethanol. The mass ratio of the microsphere to the paclitaxel-ethanol solution is 30:1.
[0034] The test results show that the drug loading of the acrylic microspheres carrying paclitaxel is 380±21ug paclitaxel / mg microsphere, and the encapsulation rate is 10%±1.2%. The cytotoxicity and blood compatibility experiments are in compliance with the standards. The in vivo release experiment confirms that paclitaxel can be detected in the blood within 4 days after embolism, and the in vitro release experiment confirms that the cumulative drug release reaches 46% in 7 days. Therefore, the acrylic microspheres carrying paclitaxel of the utility model can be used for intravascular interventional treatment, which not only has a good embolism effect, but also has a small toxic and side effect of paclitaxel sustained-release drugs and can well inhibit vascular endothelial cells and smooth muscle cells, thereby improving clinical efficacy.
[0035] When 1 mg of acrylic microspheres with a size of 100-300 μm were immersed in 1 mL of paclitaxel-anhydrous ethanol solution (50 mg / mL) for 30 minutes, the maximum drug loading amount was 380±20 μg of paclitaxel. After 60 minutes, the drug loading basically maintained equilibrium, with a drug loading amount of 385±19 μg of paclitaxel. Figure 3 As shown. 10 mg of sieved paclitaxel-carrying microspheres were taken and immersed in a test tube containing 5 mL of phosphate buffer solution with a pH of 7.4. The test tube was sealed and placed in a constant temperature water bath oscillator at 37°C to detect the drug release properties of the paclitaxel-carrying microspheres. 50 μL of supernatant was taken at 12h, 24h, 2d, 3d, 4d, 5d, 6d and 7d, respectively, and detected by high performance liquid chromatography and calculated to calculate the cumulative release of paclitaxel at different time points (50 μL of phosphate buffer solution was immediately added after taking the supernatant). The experiment was repeated three times and the average value was taken. The results are shown as follows Figure 4 As shown. Figure 3 and Figure 4The drug loading curve and release curve can fully prove that paclitaxel can be loaded on the blank microspheres. Therefore, the load of the utility model can be stably loaded on the surface and inside of the microspheres through the surface adsorption force of the honeycomb microspheres, and the adsorption force is sufficient to support the precipitation of the load.
[0036] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by any technician familiar with the technical field within the technical scope disclosed in the present invention should be included in the protection scope of the present invention.
Claims
1. An acrylic microsphere carrying paclitaxel, characterized in that: include: The microspheres are honeycomb-shaped as a whole, and the microspheres are acrylic microspheres, and any cut surface of the microspheres is a honeycomb structure; The loading substance is disposed on the surface and inside of the microspheres. The loading substance is paclitaxel. The loading substance is disposed in an amount of 380±21 ug paclitaxel / mg microspheres, and the encapsulation rate is 10%±1.2%.
2. The acrylic microspheres carrying paclitaxel according to claim 1, characterized in that: The particle size of the microspheres is 10 to 500 μm.
